dxpx general logo white text

DxPx U.S. Conference for Investors

A partnering conference for investors looking for the most exciting companies in the industry

DxPx U.S. 2025: Details to Be Announced Soon

Why Investors Should Attend DxPx:

DxPx’s Early-Stage investors include:

    • Venture Capitalists
    • Corporate VC
    • Angel Investors
    • Accelerator & Incubators – join our Ambassador Network
    • Private Investors

 

  • Meet right in the heart of the ADLM 2024 Clinical Lab Expo and schedule 1×1 meetings with startups in our private DxPx meeting spaces.


    And visit our exhibitors in Startup City, featuring some of the most exciting new companies in Diagnostics, Digital Health, Precision Medicine, and Life Sciences Tools.

 

  • Attend DxPx U.S. for free by registering as a judge for our 42PLUS1 pitch competition, which also gains you access to the entire 42PLUS1 2024 application database.

 

  • Network with all DxPx attendees at our Cocktail Reception on Tuesday, July 30th. Take some time to connect and unwind with your industry peers on-site in the DxPx reception area.

 

  • Learn from our DxPx panelists and speakers about the latest industry trends and market insights. And hear presentations from a select group of startups to learn more about their businesses and growth plans, live from the DxPx stage.

 

  • Attend the exciting final round of our 42PLUS1 pitch competition, taking place live at DxPx U.S. this year, and watch as one of our startups takes home up to $2 million in funding.

 

  • Grow your portfolio by leveraging all that DxPx U.S. has to offer.

DxPx’s Growth-Stage investors include:

    • Private Equity
    • Late-Stage VC
    • Investment Funds

 

  • Meet right in the heart of the ADLM 2024 Clinical Lab Expo and schedule 1×1 meetings with startups in our private DxPx meeting spaces.

 

  • Attend DxPx U.S. for free by registering as a judge for our 42PLUS1 pitch competition, which also gains you access to the entire 42PLUS1 2024 application database.

 

 

  • Network with all DxPx attendees at our Cocktail Reception on Tuesday, July 30th. Take some time to connect and unwind with your industry peers on-site in the DxPx reception area.

 

  • Learn more from our DxPx panelists and speakers about the latest industry trends and market insights.

 

  • Watch the exciting final round of our 42PLUS1 pitch competition, taking place live at DxPx U.S. this year, and watch as one of our startups takes home  up to $2 million in funding.

 

  • Grow your portfolio by leveraging all that DxPx U.S. has to offer. 
Join the DxPx Investor Ambassador Program to Gain Registration Discounts for Your Network

Learn more and register here.

Investor Attendee Registration Terms & Conditions:

  • All Investor registration requests are subject to review and approval by DxPx. DxPx reserves the right to cancel the registration of any individual who does not qualify as an Investor, as defined by DxPx, and to refund their registration fee. This ruling will be strictly applied for any advisors, consultants or service providers who register as investors but rather assist companies in finding investors or advise on fund raising activities.
  • All free Investor registrations require participation in 42PLUS1 pitch competition as a judge.
  • All Investors claiming a free registration to DxPx will be required to rate at least 5 startup applications to 42PLUS1.
  • Any Investor claiming a free registration to DxPx who does not rate at least 5 42PLUS1 applications by [DATE TBD] may be invoiced the full registration amount ($1,499).
  • Any Investor who claims a free registration, but who does not check in on-site at the DxPx U.S. conference by noon CST on Tuesday, July 30th, may be invoiced a no-show fee of $350.

 

Please feel free to contact us with any questions. 

Examples of Investors & Industry Companies
Attending In-Person at DxPx U.S. 2024  

Date & Location:

July 30 – August 1, 2024 in Chicago, IL at the ADLM 2024 Clinical Lab Expo

McCormick Place Convention Center
2301 South King Dr., Chicago, IL 60616

Oliver Dick

Oliver brings 30+ years of experience in the life sciences industry, has worked in pharma, biotechnology and in vitro diagnostics. His areas of expertise fall under Supply Chain Management, Planning, Production, QC, QA, Engineering, Technology Transfer and Process Improvement. Amongst his vast experience, Oliver held functions such as Vice President of Global Manufacturing at QIAGEN, Chief Operating Officer at Miltenyi Biotec or Chief Operating Office of Resolve Biosciences. He demonstrated exceptional leadership and expertise in driving manufacturing excellence on a global scale.

Oliver has a proven ability to streamline processes, optimize production efficiency, and foster a culture of innovation. He was responsible for strategy development, scaling, cost control and quality and was part of multiple M&A projects and transfer of many new products from acquisition or own development. Today Oliver offers his expertise mainly through his own Consultancy Service Company ODICON.

Experience

Christoph Brandenberger is a Managing Director at BGL and a leader in the firm’s Diagnostics, Research Tools & Medical Devices investment banking group. He has more than 20 years of experience in all aspects of mergers and acquisitions, commercialization and partnering agreements, and private placements.

A native of Austria and fluent in German, Christoph’s investment banking experience, coupled with his background in international business, has made him a sought-after advisor in both the domestic and international healthcare markets.

Prior to joining BGL, Christoph served as managing director for Healthios Capital Markets, LLC. Christoph started his career as a financial analyst for Bank of America Securities.

Experience

John Riddle

John Riddle is a Managing Director and member of the BGL Executive Committee. He has more than 30 years of investment banking and capital markets experience, advising clients across a broad spectrum of mergers and acquisitions, capital markets activities, and strategic assignments.

John leads BGL’s advisory activities in the Healthcare & Life Sciences investment banking group, which comprises both corporate investment banking and real estate capital markets capabilities. Together with his team, John maintains an ongoing coverage effort with broad activity across several sectors, including health facilities, physician services, and ancillary providers; diagnostics and research tools; medical device and products; and select healthcare technology verticals, including payor services, data analytics, and clinical automation.

Experience

Dr. Mirko Stange

Born in Bremen, Germany in 1974, Dr. Mirko Stange is a diagnostics and life sciences expert with a proven track record in turning around and commercializing innovations. He possesses extensive executive management experience, having led diagnostics and biotech startups, as well as developing and conducting consulting products. Following the completion of his Ph.D. in Biochemistry and Biophysics at the University of North Carolina at Chapel Hill, Dr. Stange began his career in 2004 at the strategy consultancy McKinsey. Subsequently, he worked with the turnaround-specialized advisory firm Droege & Comp., primarily serving clients from the pharma and chemistry industry in Germany and Switzerland.

In 2008, he founded an independent Life Sciences consultancy in Germany where, to date, he leads and directs a team of international experts. This team identifies and funds SMEs with high potential for national and international leverage. In addition to his over ten years of experience in independent corporate finance and management consulting, Mirko Stange provides interim management services to selected clients. To date, three companies co-founded and managed/advised by Dr. Stange have been successfully exited. Leveraging his scientific background, he is also a named inventor on several granted and pending patents.

Experience

FName LName

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Experience